Avedro, Inc., a Boston-based ophthalmic pharmaceutical and medical device company, announces that it has recently sold its 500th corneal cross-linking device outside of the United States.

Avedro is currently working with key ophthalmic opinion leaders to advance the use of cross-linking into primary refractive correction for conditions such as low myopia, hyperopia, astigmatism and post-cataract residual refractive errors.

Read More